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Abstract: Oyster extracts have been reported to have many bioactive peptides. But the 
function of oyster peptides produced by proteolysis is still unknown. In this study, the 
oligopeptide-enriched hydrolysates from oyster (Crassostrea gigas) were produced using 
the protease from Bacillus sp. SM98011 at laboratory level, and scaled up to pilot (100 L) 
and plant (1,000 L) levels with the same conditions. And the antitumor activity and 
immunostimulating effects of the oyster hydrolysates in BALB/c mice were investigated. 
The growth of transplantable sarcoma-S180 was obviously inhibited in a dose-dependent 
manner in BALB/c mice given the oyster hydrolysates. Mice receiving 0.25, 0.5 and   
1 mg/g of body weight by oral gavage had 6.8%, 30.6% and 48% less tumor growth, 
respectively. Concurrently, the weight coefficients of the thymus and the spleen, the 
activity of natural killer (NK) cells, the spleen proliferation of lymphocytes and the 
phagocytic rate of macrophages in S180-bearing mice significantly increased after 
administration of the oyster hydrolysates. These results demonstrated that oyster 
hydrolysates produced strong immunostimulating effects in mice, which might result in its 
antitumor activity. The antitumor and immunostimulating effects of oyster hydrolysates 
prepared in this study reveal its potential for tumor therapy and as a dietary supplement 
with immunostimulatory activity. 
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1. Introduction  
Enzymatic hydrolysis is an attractive method for modifying the physical properties of food proteins 
to improve their nutritional properties [1]. The application of enzyme technology to recover modified 
food proteins may produce a broad spectrum of food ingredients or industrial products [2–4]. Recent 
studies have demonstrated the capacity of enzymes to produce novel food products, modify foodstuffs 
and improve waste management [1,5–7]. 
In recent years, opportunistic or complicated infections often lead to stress-associated 
immunosuppression, which are difficult to treat with antibiotics alone and continue to be a challenge in 
the clinical field [8]. Moreover, most immunomodulatory pharmaceuticals are not suitable for chronic 
or preventive use. Therefore, there is an increasing interest in identifying new immunomodulators to 
enhance nonspecific host defense mechanisms [8]. Immune peptides are a group of extremely diverse 
small proteins that are suitable as biocontrol agents because they: (i) have a broad spectrum of target 
microorganisms, including bacteria, fungi and viruses; (ii) have not, to date, induced pathogen 
resistance; (iii) are generally non-toxic, and can meet food safety requirements. Many immune 
peptides have been reported in hydrolysates from food proteins digested with proteases [9], but most of 
them are from terrestrial proteins rather than from marine sources. The composition and primary amino 
acid sequences of marine proteins are different from those of terrestrial proteins. Therefore, marine 
proteins may be an important resource for novel immune peptides following enzymatic hydrolysis. 
Indeed, peptides isolated from fish hydrolysates show strong immunostimulating effects [10,11]. The 
immunostimulant activity of enzymatic protein hydrolysates from microalgae Chlorella has also been 
demonstrated in mice [12]. Pulz and Gross reported that the world production of Chlorella amounts to 
2,000 ton/year and the product is applied in the protein enrichment of functional foods and nutritional 
supplements [13].  
Oyster proteins are a potential resource for active bio-peptides. It has been reported that oyster 
extracts have many bioactive peptides, such as ACE (angiotensin-converting enzyme) inhibitory 
peptides [14], anti-fungal peptides [15] and anti-cancer peptides [16]. Thus, oyster proteins are likely 
to contain a large amount of various bioactive sequences. These bioactive sequences can be released 
by enzyme hydrolysis to serve as bioactive peptides, and therefore, enzyme hydrolysis may improve 
the nutritional properties of oyster proteins.  
In this study, oyster (Crassostrea gigas) hydrolysates were prepared with the protease from   
Bacillus sp. SM98011 and production was scaled up to pilot and plant scales. The antitumor activity Mar. Drugs 2010, 8                              
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and immunostimulating effects of plant-scale oyster hydrolysates on S180-bearing BALB/c mice were 
investigated. The results showed that the oyster hydrolysates had obvious antitumor activity and 
enhanced immune function in BALB/c mice, implying that the oyster hydrolysates may have potential 
in tumor therapy and as a dietary supplement with immunostimulatory activity. 
2. Experimental Section  
2.1. Materials 
Pacific oysters (C. gigas) were bought at a local fish market. Protease was prepared from Bacillus 
sp. SM98011 and an activity assay was performed using the methods previously described [17]. 
Concanavalin A (Con A), Wright-Giemsa stain and 3-(4,5-dimethylththiazoyl-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) were purchased from Sigma (USA). RPMI-1640 and fetal bovine 
serum (FBS) were purchased from Gibco (USA). Mouse lymphadenoma YAC-1 cell lines (sensitive to 
NK cells), and S180 mouse sarcoma cell lines were purchased from Shandong Academy of Medical 
Sciences, China. 
2.2. Production of oyster hydrolysates on a laboratory scale and its scale-up to pilot and plant levels 
Hydrolysis of the oysters was performed on a laboratory scale (500 mL Erlenmeyer flask), pilot 
scale (100 L thermostatically stirred-batch reactor) and plant scale (1,000 L thermostatically   
stirred-batch reactor). For the laboratory scale, a reaction mixture consisting of 50 g of minced oysters 
and 10 mL crude protease solution (400,000 U/kg, enzyme/fresh weight of protein substrate) in a  
500 mL Erlenmeyer flask was adjusted to pH 7.5 with NaOH or HCl. The reactor vessel was placed in 
a thermostatically controlled water-bath with constant agitation (200 rpm) at 50 °C. After 5 h, the 
reaction was stopped with a 15-min incubation at 90 °C [18]. The resulting slurry was centrifuged at 
9,000 ×g for 20 min at 4 °C. The supernatant was lyophilized and stored at 4 °C until further analysis. 
For the pilot and plant scales, minced oysters were mixed with water at a ratio of 1:1 (w/w) by 
continuous stirring and the enzyme was added with 400,000 U/kg. All reactions were performed at  
pH 7.5 and 50 °C for 5 h with constant agitation (200 rpm). The reactions were terminated by heating 
the solution to 90 °C for 15 min, assuring the complete inactivation of the enzyme. The resultant slurry 
was centrifuged at 9,000 ×g for 20 min and the supernatant was oyster hydrolysates. The hydrolysates 
from pilot and plant scales were condensed with a ball vacuum concentration tanker (RD500, GuanYi 
Mechanical Equipment Co., Ltd, China) and were dried with a spray dryer (BoDa Co., China) at a  
10 kg/h flow rate with a 170 °C inlet temperature and 90 °C outlet temperature [19]. 
2.3. Characterization of oyster hydrolysates 
Assays of the peptides and amino acids in the hydrolysates were performed using the methods 
previously described [20]. The peptides larger than 3 kDa were removed by ultrafiltration with an 
ultrafiltration membrane (molecular weight cut-off 3 kDa). Fraction analysis of the peptides in the 
hydrolysates was performed using reversed phase high-performance liquid chromatography   
(RP-HPLC, Waters alliance 2695, USA) coupled with a Dual Wavelength UV Detector 2487 on a 
Symmetry (Waters, Milford, MA, USA) C18 column (250 mm × 4.6 mm). Separation was performed Mar. Drugs 2010, 8                              
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with a linear gradient of acetonitrile from 6.7% to 40% containing 0.1% trifluoroacetic acid for 30 min 
followed by a linear gradient of methanol from 40% to 6.7% for 15 min at a flow rate of 1 mL/min. 
Peptides were monitored at 214 nm. 
2.4. Animals 
Seventy female BALB/c mice (20 ± 2 g, 6–8 weeks old) were purchased from the Animal Center, 
Medical Institute of Shandong University, China. The mice were housed under normal laboratory 
conditions (21 ± 2 °C) with free access to standard rodent chow and water. To transfer the tumor cells 
to the mice, 0.2 mL of S180 cell suspension (5 × 10
6 cells/mL) was subcutaneously inoculated into a 
mouse armpit. The mice were divided into 7 groups of 10 animals each: normal control group,   
S180-bearing control group, 0.25, 0.5 and 1 mg/g oyster hydrolysates (ultrafiltered) treated groups,  
1 mg/g crude oyster hydrolysates (not ultrafiltered) treated group and 0.02 mg/g cyclophosphamide 
(CTX) treated group. The oyster hydrolysates were administrated by oral gavage once a day for 14 d in 
the treated groups. Normal control and S180-bearing control groups received the same volume of 
physiological brine. The CTX treated group was treated with the standard anti-cancer drug cytoxan by 
intraperitoneal injection. On the 15
th day, all the animals were sacrificed and the mice, thymuses, 
spleens and tumors were weighed. The present study was performed in accordance with the Guidelines 
in the Care and Use of Animals and was approved by the Center for New Drugs Evaluation of 
Shandong University’s review committee and Shandong University’s Animal Ethics Committee. 
2.5. Analysis of the spleen and thymus indices of the mice 
The spleens and thymuses were eviscerated out of the mice and weighed to obtain the indices of the 
spleen and thymus. The spleen index (mg/g) = spleen weight/body weight, and the thymus   
index (mg/g) = thymus weight/body weight. The antitumor activity of oyster hydrolysates was 
expressed as an inhibition ratio calculated as [(A-B)/A] × 100%, where A and B were the average tumor 
weights of the control and treated groups, respectively. 
2.6. Assay of lymphocyte proliferation 
The MTT test was used to measure lymphocyte proliferation following the method described by 
Denizot and Lang [21] with modifications. Spleens were aseptically removed from sacrificed mice 
with scissors and forceps and put in cold phosphate-buffered saline (PBS), gently homogenized and 
filtered with a fine nylon mesh to obtain single cell suspensions. Then the cells were suspended at a 
final density of 5 × 10
6 cells/mL in RPMI-1640 medium supplemented with 10% newborn bovine 
serum. Subsequently spleen cells (200 µL/well) were seeded into a 96-well plate. Con A (7 µg/mL) as 
a T cell mitogen was added to the cell suspension and the plate was incubated at 37 °C with 5% CO2. 
After incubation for 72 h, 10 µL MTT (5 mg/mL) was added to each well and the plate was further 
incubated for 4 h. The plate was centrifuged at 200 ×g for 10 min and the supernatants were removed. 
Dimethyl sulfoxide (DMSO, 100 µL) was added to each well and the plate was shaken until the 
crystals dissolved. The absorbance of each well was detected at 570 nm on a microplate reader Mar. Drugs 2010, 8                              
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(Multiscan MK3, Thermo Labsystems). The proliferation of lymphocytes = A-B, where A was the 
OD570 of the wells with Con A, and B was the OD570 of the wells without Con A. 
 
2.7. Assay of NK cell activity 
NK cell activity was measured following the method of Yuan et al. [22]. YAC-1 cells were used as 
target cells (T) and seeded in 96-well U-bottom culture plates at 1 × 10
4 cells/well in RPMI-1640 
medium. Spleen cells prepared as described above were used as the effector cells (E) and were added 
at 5 × 10
5 cells/well to give an E/T ratio of 50:1. The plates were incubated at 37 °C for 20 h in a 5% 
CO2 atmosphere. Then 10 µL MTT (5 mg/mL) was added to each well. The plate was incubated for 
another 4 h and subjected to an MTT cellular assay. Three kinds of control measurements were 
performed: a target cell control, a blank control and an effector cell control. NK cell activity was 
calculated using the following equation:  
NK cell activity (%) = % 100
OD
) OD OD ( OD
T
E S T

－ －
 
where ODT is the optical density value of the target cell control. ODS is the optical density value of the 
test samples, and ODE is the optical density value of the effector cell control. 
2.8. Assay of macrophage phagocytosis 
Macrophage phagocytosis was assessed following the method described by Wang et al. [23] with 
modifications. First, peritoneal exudate macrophage were harvested from BALB/c mice 3 d after 
intraperitoneal injection of 1 mL of 2% aqueous starch suspension, and were collected into sterile  
2 mL tubes. Chicken erythrocytes (0.5 mL, 1% in Hanks’ solution) and 0.5 mL of mouse macrophage 
were mixed. A sample of the resulting suspension (0.5 mL) was spread on glass slides and incubated 
for 20 min in a 37 °C, 5% CO2 incubator. After incubation, the glass slides were washed with saline to 
remove unattached cells. Then the slides were treated with methyl alcohol for 5 min and dyed 
with 4% (v/v) Giemsa-PBS buffer solution. The number of macrophage that ingested chicken 
erythrocytes was counted under a microscope. The data are presented as the phagocytic rate (%) 
(macrophage that ingested chicken erythrocytes/total macrophage) and the phagocytic index (ingested 
chicken erythrocytes/total macrophage). 
2.9. Statistical analysis 
Data are presented as the arithmetic mean ± standard deviation (SD) of triplicate samples. Statistical 
analysis was performed using SPSS 10.0. Statistical analysis (Student’s t-test) was based on 
comparisons between the S180 control group and the treated groups. P values less than 0.05 were 
considered statistically significant. Mar. Drugs 2010, 8                              
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3. Results 
3.1. Production and characterization of the oyster hydrolysates generated on laboratory, pilot and 
plant scales 
Oyster hydrolysates were first produced with crude protease SM98011 on a laboratory scale. The 
peptide content in the oyster hydrolysates prepared on a laboratory scale was 62.4% and total amino 
acid content was 67.6%. Then oyster hydrolysate production was scaled up to pilot (100 L) and plant 
(1,000 L) levels. In pilot- and plant-scale product, the peptide content was 58.6% and 57.9%, and the 
total amino acid content was 67.8% and 69.8%, respectively. These results were similar to the 
laboratory scale (Table 1). Therefore, after production was increased to the pilot- and plant-scale 
levels, the properties and the compositions of the oyster hydrolysates remained fairly consistent with 
those on a laboratory scale. 
Table 1. Amino acid compositions of oyster hydrolysates produced at different scales. 
Amino acid 
Lyophilized 
hydrolysates at 
laboratory scale  
(g/100 g) 
Spray dried 
hydrolysates at pilot 
scale (g/100 g) 
Spray dried 
hydrolysates at plant 
scale (g/100 g) 
Asp 6.26  6.39  6.63 
Ser 2.69  2.75  2.98 
Glu 9.15  9.24  9.27 
Gly 3.85  3.66  3.51 
His 1.71  1.65  1.77 
Arg 7.98  8.40  8.12 
Thr 2.82  2.72  2.76 
Ala 3.70  3.67  3.86 
Pro 2.74  2.76  2.97 
Cys 0.23  0.22  0.21 
Tyr 0.65  0.65  0.76 
Val 1.52  1.55  1.64 
Met 3.82  3.82  3.94 
Lys 4.24  4.21  4.42 
Ile 3.91  3.96  4.17 
Leu 6.17  6.30  6.53 
Phe 6.15  5.85  6.28 
Total 67.59  67.80  69.82 
 
The peptide spectra of the products from laboratory, pilot and plant volumes were analyzed with 
RP-HPLC chromatography. The result showed that the peptide spectra of the hydrolysates at pilot and 
plant scales were identical to those from the laboratory scale (Figure 1). Therefore, the optimized 
conditions for oyster hydrolysate production on a laboratory scale were well suited for pilot- and plant-
scale production. Hydrolysates produced on a plant scale were condensed with a vacuum evaporator 
and then were dried with a spray dryer. The dried hydrolysate powder dissolved easily in water and its 
solution was clear with a thin orange-green color. HPLC analysis revealed no significant differences Mar. Drugs 2010, 8                              
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between the non-dried hydrolysates and the dried powder (Figure 2), indicating that exposing the 
hydrolysates to high temperature did not destroy the composition of the peptides. Therefore, the 
oligopeptide-enriched hydrolysates from oysters were heat stable. 
Figure 1. Peptide spectra of oyster hydrolysates produced on laboratory, pilot and plant 
scales. Hydrolysates were analysed by RP-HPLC on a C18 column under the conditions 
described in materials and methods. 
 
 
Figure 2. Effects of spray drying on the peptide composition of the oyster hydrolysates. 
Hydrolysates were analyzed by RP-HPLC on a C18 column under the conditions described 
in materials and methods. 
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3.2. Antitumor activity of oyster hydrolysates on S180-bearing mice and their effects on thymus and 
spleen indices 
Treatment with 0.5 and 1 mg/g plant-scale hydrolysates significantly inhibited the growth of 
transplanted sarcoma S180 cells with inhibitory rates of 30.6% and 48%, respectively. Dose-dependent 
inhibition of tumor growth is shown in Table 2. Meanwhile, all the groups treated with oyster 
hydrolysates had a significant increase in the thymus and spleen indices compared with S180 control 
group, indicating that oyster hydrolysates may function as an immunostimulator in S180-bearing mice. 
In contrast, the chemotherapy drug, CTX had a noticeable inhibitory effect on mouse transplanted 
sarcoma S180, but also significantly decreased the spleen and the thymus indices (Table 2). These 
results suggest that oyster hydrolysates probably inhibited the growth of tumor cells by improving the 
immune function in S180-bearing mice. 
Table 2. Effects of oyster hydrolysates on the transplanted tumors and thymus and spleen 
indices in S180-bearing mice. 
Groups  Tumor weight (g) 
Inhibition rate 
(%) 
Thymus index  
(mg/g) 
Spleen index  
(mg/g) 
Normal control  -  -  0.6480 ± 0.1143
*  6.0961 ± 0.3930
*** 
CTX  0.449 ± 0.118
***  82.5  0.5953 ± 0.0565
**  5.6334 ± 1.0100
** 
S180 control  2.567 ± 0.077  -  0.8154 ± 0.0740  8.8186 ± 0.3967 
a 0.25 mg/g  2.393 ± 0.111  6.8  0.6969 ± 0.1410  9.4700 ± 1.1800 
a 0.5 mg/g  1.781 ± 0.226
**  30.6  0.8665 ± 0.0100  9.4267 ± 0.7975 
a 1 mg/g  1.335 ± 0.066
***  48.0  1.0014 ± 0.0898
*  10.7345 ± 0.7030
** 
Crude 
b  
(1 mg/g) 
1.922 ± 0.216
**  25.1  0.9397 ± 0.1937
**  10.2135 ± 0.6570
* 
Values are presented as mean ± SD. 
*Significantly different from S180 control group at P < 0.05. 
**Significantly different from S180 control group at P < 0.01. 
***Significantly different from S180 
control group at P < 0.001. 
a Ultrafiltered hydrolysates; 
b Not ultrafiltered hydrolysates. 
3.3. Effects of oyster hydrolysates on cellular immunity in S180-bearing mice 
Tumor cell elimination is known to be mediated in part by the cytotoxic activity of NK cells [22]. 
Therefore, the cytotoxic activity of splenocytes against NK-sensitive tumor cells (YAC-1) was 
measured. As shown in Table 3, spleen lymphocyte proliferation and NK cell activity were 
significantly decreased in the group treated with CTX in comparison with S180 control group. In 
contrast, in all 3 groups treated with different amounts of oyster hydrolysates, NK cell activity was 
significantly increased, and lymphocyte proliferation was also obviously increased in the mid- and 
high-dose groups. Therefore, oyster hydrolysates enhanced cell-mediated immunity in   
S180-bearing mice. Mar. Drugs 2010, 8                              
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Table 3. Effects of oyster hydrolysates on spleen lymphocyte proliferation and NK cells 
activity in S180-bearing mice. 
Groups  NK activity (%) 
Lymphocyte proliferation  
A570 
Normal control  42.22 ± 12.60  0.6800 ± 0.0735
* 
CTX  20.70 ± 6.76
*  0.1589 ± 0.0868
** 
S180 control  29.37 ± 8.83  0.5070 ± 0.0558 
a 0.25 mg/g  43.64 ± 9.70
*  0.7084 ± 0.1807 
a 0.5 mg/g  51.65 ± 9.69
**  0.8219 ± 0.0256
*** 
a 1 mg/g  58.35 ± 12.50
***  0.8640 ± 0.0456
*** 
Crude 
b (1 mg/g)  44.30 ± 12.10
*  0.7536 ± 0.1196
* 
Values are presented as mean ± SD. 
*P < 0.05. 
**P < 0.01. 
***P < 0.001. 
a Ultrafiltered hydrolysates;  
b Not ultrafiltered hydrolysates. 
3.4. Effects of oyster hydrolysates on macrophage phagocytosis in S180-bearing mice 
Phagocytosis by macrophage is one of the most important nonspecific immune responses in the 
human body. The effects of oyster hydrolysates on macrophage phagocytosis were investigated by 
measuring the phagocytic rate and phagocytic index. Compared with the S180 control group, CTX 
treatment markedly decreased the phagocytic activity and phagocytic index, while oyster hydrolysates 
significantly increased the phagocytic rate (p < 0.05) in a dose-dependent manner in S180-bearing 
mice (Table 4). However, none of the 3 doses of oyster hydrolysates had a significant effect on the 
phagocytic index. This result indicated that the increased phagocytic activity caused by oyster 
hydrolysates in S180-bearing mice resulted from an increase in the number of total phagocytes, rather 
than the activation of phagocytes. 
Table 4. Effects of oyster hydrolysates on macrophage phagocytosis in S180-bearing mice. 
Groups  Phagocytic rate (%)  Phagocytic index 
Normal control  50.0 ± 3.6  1.077 ± 0.045 
CTX  37.3 ± 1.5
*  0.650 ± 0.036
* 
S180 control  46.0 ± 1.0  1.130 ± 0.061 
a 0.25 mg/g  45.7 ± 1.5  1.073 ± 0.059 
a 0.5 mg/g  54.3 ± 2.1
*  0.970 ± 0.070 
a 1 mg/g  61.0 ± 3.6
*  1.173 ± 0.061 
Crude 
b (1 mg/g)  43.0 ± 2.7  0.953 ± 0.050 
Values are presented as mean ± SD. 
*P < 0.05. 
**P < 0.01. 
***P < 0.001. 
a Ultrafiltered hydrolysates; 
b Not ultrafiltered hydrolysates. Mar. Drugs 2010, 8                              
 
 
264
4. Discussion 
Oyster extracts have been consumed since the 1970s as a dietary supplement, particularly in Japan. 
They chiefly contain transient elements including iron, copper and zinc, as well as amino acids, 
including high concentrations of glutamic acid and taurine [24]. Over the years most of the studies on 
oysters have focused on the biological activities of oyster extracts. It has been reported that oyster 
extracts can stimulate glutathione expression [25], significantly enhance IL-2 dependent T-cell 
proliferation [24], and exhibit antioxidant characteristics [26,27]. A peptide that inhibits HIV-1 
protease was also isolated from C. gigas hydrolysates [28]. However, reports on the 
immunomodulating activity of oyster protein hydrolysates produced by enzyme technology are rare. 
As dietary proteins, oyster proteins are likely to contain a large amount of bioactive sequences, which 
may serve as a potential resource for immunomodulators. In this study, we investigated the immune 
potential of oyster hydrolysates for the first time. Bioactive hydrolysates of oysters produced with the 
protease from Bacillus sp. SM98011 were produced on a laboratory scale and successfully scaled up to 
pilot and plant levels. Oral administration of the oyster hydrolysates produced on a plant scale 
markedly inhibited S180 tumor cell growth, and enhanced immune function in S180-bearing mice.  
The relative weights of the spleen and thymus are important indices of nonspecific immunity. It was 
reported that oral administration of immunopotentiators increased the weights of spleens and thymuses 
in S180-bearing mice [29]. Our results showed that the relative weights of spleens and thymus 
increased significantly in a dose-dependent manner in the mice treated with oyster hydrolysates, 
suggesting that oyster hydrolysates probably function as an immunostimulator. 
Immune responses, especially cellular immunity, play an important role in the elimination of tumor 
cells, and thus inhibit tumor growth. Cell-mediated immune defence is mediated specifically by T cells 
including NK cells [30]. In S180-bearing mice treated with oyster hydrolysates, there was a significant 
increase in NK cell activity while tumor growth was inhibited, suggesting that the increased NK cell 
activity caused by oyster hydrolysates played an important role in eliminating tumor cell growth. 
Lymphocyte proliferation is also an important indicator of immunoactivation. Stimulating 
lymphocytes with ConA in vitro may be used to evaluate T lymphocyte activity [31]. Oral 
administration of oyster hydrolysates caused a significant increase in lymphocyte proliferation in the 
mid and high-dose groups of S180-bearing mice, indicating that oyster hydrolysates enhanced the 
mitogenic activity of splenic lymphocytes by functioning as a T-cell adjuvant. Bovine lactoferrin 
hydrolysates have also been reported to induce an antigen-specific proliferative response in T 
lymphocytes and NK cells [32]. This response may be due to cytokines released from cells in the 
mucosa of the small intestine [33]. 
Macrophage play an important role in making innate and adaptive immunities function 
cooperatively and interdependently [34,35]. Phagocytosis is one of the most important nonspecific 
immune responses of the body. Therefore, stimulating macrophage is a major target for therapeutic 
applications [36]. Our results showed that oyster hydrolysates significantly enhanced the phagocytic 
rates of macrophage, but had no obvious effect on the phagocytic index. Duarte et al. reported that fish 
protein hydrolysates increased the percentage of phagocytosis by peritoneal macrophages in mice [37].  
As a well known antitumor drug, CTX has a high tumor inhibitory rate. However, our results and 
other reports have shown that CTX also has a strong immunosuppressive effect [31]. In contrast, Mar. Drugs 2010, 8                              
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oyster hydrolysates inhibited tumor growth by improving the immune function in S108-bearing mice, 
which suggests its potential in tumor therapy. In addition, oyster hydrolysates have potential as a 
dietary supplement that can act as an immunostimulant or as an adjuvant to improve immune function 
in vivo. Since the oyster hydrolysates used in this study were not further purified beyond ultrafiltration, 
high doses were needed to cause immunomodulating activities in the mice. The potent 
immunostimulating components in the oyster hydrolysates are being purified to evaluate their potential 
value in the treatment of human cancers.  
5. Conclusions 
The function of oyster peptides produced by proteolysis is still unknown. In this study, the 
oligopeptide-enriched hydrolysates from oyster were produced using the protease from   
B. sp. SM98011 at laboratory level, and scaled up to pilot (100 L) and plant (1,000 L) levels. The 
antitumor activity and immunostimulating effects of the oyster hydrolysates produced at plant scale in  
BALB/c mice were investigated. The growth of transplantable sarcoma-S180 was obviously inhibited 
in a dose-dependent manner in BALB/c mice given the oyster hydrolysates. Concurrently, the weight 
coefficients of the thymus and the spleen, the activity of natural killer (NK) cells, the spleen 
proliferation of lymphocytes and the phagocytic rate of macrophages in S180-bearing mice 
significantly increased after administration of the oyster hydrolysates. These results indicated that 
oyster hydrolysates produced strong immunostimulating effects in mice, resulting in its antitumor 
activity. The antitumor and immunostimulating effects of oyster hydrolysates prepared in this study 
reveal its potential for tumor therapy and as a dietary supplement with immunostimulatory activity. 
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